Contemporary principles of diagnostic and therapeutic management in cervical and ovarian neuroendocrine tumors by Bidzinski, Mariusz et al.
312
RE VIE W PAPER /  GYNECOLOGY
DOI 10.5603/GP.a2020.0189
Ginekologia Polska
2021, vol. 92, no. 4, 312–317
Copyright © 2021 Via Medica
ISSN 0017–0011, e-ISSN 2543–6767
Corresponding author:
Szymon Piatek
Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland
e-mail: szymon.piatek@aol.com
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Contemporary principles of diagnostic  
and therapeutic management in cervical  
and ovarian neuroendocrine tumors
Mariusz Bidzinski1 , Szymon Piatek1 , Jaroslaw Cwikla2 ,  
Anna Nasierowska-Guttmejer3, 4 , Anna Danska-Bidzinska5
1Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland 
2Department of Radiology, University of Warmia and Mazury, Olsztyn, Poland 
3Pathology Department, Central Clinical Hospital of the MSWiA, Warsaw, Poland 
4Lazarski University, Warsaw, Poland 
52nd Clinic of Obstetrics and Gynecology, Medical University of Warsaw, Poland
ABSTRACT
Enhancing knowledge about neuroendocrine neoplasms causes the need to improve management of these tumors. Al-
though these tumors are rare in clinical practice, their biological diversity makes both diagnostics and therapy a challenge 
for contemporary oncology. The article discusses the latest developments in the diagnostic procedures and methods of 
treatment of the cervical and ovarian neuroendocrine tumors. Algorithms are presented to understand the differences in 
therapeutic management in these malignancies.
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INTRODUCTION
Primary neuroendocrine neoplasms /tumors (NEN/NETs) 
of female genital organs require a separate approach due to 
extremely aggressive course. These tumors present as het-
erogeneous group with an incidence of about two percent 
of all female genital cancers [1, 2]. The cervix and ovaries 
are the most common locations of neuroendocrine tumors 
within the female reproductive system; only isolated cases 
have been described in the uterine corpus. NEN metastases 
from the gastrointestinal tract, lungs and thymus should be 
always excluded, especially in ovaries involvement. These 
tumors require an appropriate histopathological assess-
ment and should be distinguished from other primary ovar-
ian neoplasms, particularly granulosa cell tumor.
The terminology of neoplasm, commonly called carci-
noid, has been changed since 2000 [3]. European Neuroen-
docrine Tumor Society, due to new opportunities in somato-
statin receptor-targeted therapy within the neoplastic cells, 
distinguished two basic groups in NEN: low-grade neuroen-
docrine neoplasms/tumors (LG NENs/NETs) microscopically 
resembling carcinoids, and high-grade neuroendocrine neo-
plasms/tumors ( HG NENs/NETs) with cancer morphology.
CERVICAL NENS
Nowadays, according to the WHO classification from 2014, 
cervical LG NENs are divided into the following groups [4]: 
•	 low grade neuroendocrine tumors (TC, carcinoid tumor),
•	 low grade neuroendocrine tumors, G1
•	 low grade neuroendocrine tumors, (AC, atypical carci-
noid tumor),
•	 low grade neuroendocrine tumors, G2.
Cervical HG NENs referred to as neuroendocrine carci-
noma G3 (NEC) should be classified as tumors of the diges-
tive system. The WHO classification distinguishes small cell 
neuroendocrine carcinoma (SCNEC) and large cell neuroen-
docrine carcinoma (LCNEC).
Cytological diagnostics
Pap smears are of little use in detecting early forms of 
the cervical NEN. Only for an experienced cytopathologist 
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or pathologist, the cytological test raises suspicion of NEN. 
Chiang et al. recorded 57.5% normal smear in a group of 
133 patients with SCNEC. The authors found that false nega-
tive results were significantly higher compared to squamous 
cell cervical cancer [5]. In another study, abnormal cytology 
was detected in 14–45.5% of cases [6]. Zhou et al. [7] pre-
sented an analysis of cytological smears from 11 patients 
with cervical NEN. In six cases, abnormal cells were found - 
in three patients non-specific cancer cells, in another three 
patients adenocarcinoma cells were diagnosed. Retrospec-
tive evaluation of seven smears, assessed initially as normal, 
showed abnormal cells in two patients. These cases were 
found to be false negative. Park et al. [8] observed abnormal 
cytology in 9 of 27 patients (33.33%) with cervical NEN. In two 
cases neuroendocrine tumor cells were detected in cytologi-
cal smear; the others were diagnosed with squamous cell 
carcinoma (n = 2), HSIL (n = 3), ASCUS (n = 2). Kim et al. [9] 
attempted to determine the characteristic smear features for 
cervical SCNEC. They analyzed 13 cases of cervical SCNEC and 
compared them with squamous cell carcinoma, lymphoma 
and chronic cervicitis. Cytological changes useful in differ-
ential diagnosis were found: nuclear molding and smearing 
(100%), salt and pepper chromatin (100%), exudative and 
necrotic background (91.7%), various architectures including 
individual cells (83.3%), tight clusters (75%) and feathering 
and strip (50%), and inconspicuous nucleoli (75%).
Nonetheless cervical Pap smear test is insufficient for 
the diagnosis of NEN.
Histopathological and molecular diagnostics
Macroscopically cervical NENs are not different from 
squamous cell and adenocarcinoma. Diagnosis is based on 
a histopathological examination with immunohistochemi-
cal assay. Cervical NENs differentiate from squamous and 
glandular epithelium. Neuroendocrine tumors, especially 
low grade can produce various proteins and hormones 
like calcitonin, gastrin, serotonin, substance P, vasoactive 
intestinal peptide, pancreatic polypeptide, somatostatin and 
adrenocorticotrophic hormone. Nonetheless cervical NENs 
rarely demonstrate clinical symptoms. Carcinoid syndrome 
can be found in cases with liver metastases. 
Microscopically LG NENs are characterized by organoid 
structures resembling carcinoids. Accordingly, to cell ma-
turity they are divided into two subtypes [10]. LG NEN (G1) 
differs from LG NEN G2 in nuclear atypia, mitotic activity 
and the presence of focal thrombotic necrosis. Prolifera-
tion activity of Ki-67, which has significant predictive and 
prognostic value in the NEN of the digestive system, is not 
of that importance in the NEN of the cervix. Cervical HG NEC 
G3 resembles small- and large-cell lung cancers as far as 
microscopic image is concerned. They are characterized by 
high proliferation activity, extensive infiltration and necrosis.
Diagnosis of NEN requires confirmation of immunohisto-
chemical (IHC) markers. Chromogranin A and synaptophysin 
are mandatory in every case. The expression of other mark-
ers like neuron- specific enolase (NSE) and CD56 may also be 
useful [4]. These markers are specific in 33 to 100% of small 
cell neuroendocrine tumors [10]. In some cases, particular 
in SCNENs, IHC expression of these markers may be weak. 
Recently, Japanese researchers pointed out that insulino-
ma associated protein 1 (INSM 1) is more specific than other 
markers [11]. In addition, thyroid transcription factor 1 (TTF1) 
was found to be specific in SCNET in 33% to 84% [12]. Use-
fulness of TTF1 is limited, because it did not allow to distin-
guish SCNET from primary pulmonary NEN. Due to frequent 
coexistence of cervical NENs and HPV infection (especially 
high-risk 18 type) a positive reaction to p16 protein can be 
found. In the meta-analysis published by Castle et al. [13] HPV 
16 and/or 18 infections was found in 85% of SCNENs and 88% 
of LCNENs. The activity of Ki-67 in cervical NETs is not obvious 
as in gastrointestinal tract and lung NENs. Moreover, in WHO 
classification 2014, the Ki-67 index was not included in the 
diagnostic criteria of cervical neuroendocrine tumors [4]. 
Among molecular abnormalities, mutations in the following 
genes are most common: c-myc (53%), p53 (26%), PIK3CA 
(18%). Loss of heterozygosity was found in approximately 
30% of NETs of female reproductive system [10].
Imaging diagnostics
Chest, abdominal and pelvic computed tomography 
(CT) should be performed in each case of cervical NET. PET 
CT is also recommended. Pelvic MRI or a transrectal ultra-
sound (TRUSG) examination should be additionally per-
formed in locally advanced disease. Accuracy of parametria 
involvement in tumors < 1 cm compared with the histo-
pathological examination was 98.7% and 94.7% (p < 0.219), 
respectively [14]. MRI is the method of choice for staging 
cervical NETs in pregnant women, in cases of iodine contrast 
allergy or renal failure [15].
Somatostatin receptor scintigraphy (SRS) can be helpful 
in appropriate staging or searching for the primary lesion in 
well differentiated NENs due to overexpression of the soma-
tostatin (SST) receptor. Other cervical NENs do not have sig-
nificant expression of SST receptors. In these cases, positron 
emission tomography with fluorodeoxyglucose (FDG-PET) 
is an option. FDG-PET is used in staging and has prognostic 
significance in low differentiation NENs. It can also be used 
in identification of the primary tumor, assessment of treat-
ment effectiveness or suspicion of relapse [16]. 
Clinical course, prognosis and treatment
LG NENs G1 and LG NENs G2
They account for 0.5 to 5% of all cervical cancers [17]. 
Primary LG NEN G1 is seldomly diagnosed. The metastatic 
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character of the tumor should always be excluded. The most 
common clinical symptom is vaginal bleeding. Symptoms 
of carcinoid syndrome are rarely manifested in these pa-
tients, although it is often possible to detect serum elevat-
ed concentrations of 5-hydroxyindoleacetic acid (5-HIAA). 
The clinical course of LG NEN G1 is difficult to predict due 
to its rare occurrence. LG NEN G2 is an extremely aggressive 
tumor. Between two to three-years overall survival range 
between 12.5 and 33%. Even early stage tumors may spread 
to distant locations through lymphatic drainage or blood. 
The treatment of LG NEN G2 is not standardized although 
total abdominal hysterectomy is proposed in a locally ad-
vanced tumor. Isolated liver metastases may be treated with 
transarterial chemoembolization (TACE) using streptozo-
tocin and 5-fluorouracyl. It is more effective than systemic 
treatment with paclitaxel, cis- or carboplatin, which have 
been shown to be ineffective in the treatment of LG NEN 
G2 metastases. In cases of positive somatostatin receptor, 
treatment with somatostatin analogues can be used [10, 18].
HG NENs G3
The average age of patients with SCNEN ranges from 
37 to 46 years. Lymphatic or blood metastases occur im-
mediately even in early stages of disease. Perineural invasion 
is common. Staging is the most important prognostic fac-
tor. Postoperative histopathological examination revealed 
metastases in lymph nodes in 45–57% of cases and LVSI 
involvement in 80% of cases [19, 20]. The mean overall 
survival in stage I–IIA is 31 months, while in stage IIB - IVB 
it reaches 10 months. According to SEER data, five-years 
survival in early stages ranges from 30 to 60%, and in ad-
vanced stages is 0–17% [21]. The results of treatment are 
significantly worse than in other types of the cervical cancer. 
Five-year survival in SCNENs, squamous cell carcinoma and 
adenocarcinoma are 35.7%, 60.5% and 69.7% respectively 
[22]. Tumor size is also prognostic. Five-year survival in tu-
mors ≤ 4 cm and > 4 cm was 76% and 18%, respectively.
As in other rare cancers, there is a lack of data on treatment 
based on randomized trials. The experience gathered during 
treatment of pulmonary NENs is used in therapy of gynecologi-
cal NENs. At the moment of diagnosis of SCNEN metastases are 
often found, so treatment is usually multidisciplinary.
Incidence of LCNEN is less than SCNEN but it also has 
aggressive clinical course. Most patients with LCNEN die 
within the first three years since diagnosis. Embry et al. 
[23] analysed 63 patients with LCNENs and found that the 
average survival was 16.5 months (19 months — stage I, 
17 months — stage II, 3 months — stage III, 1.5 moths 
— stage IV). Weak HER-2/Neu expression and strong EGFR 
expression appeared to be adverse prognostic factors. MD 
Anderson Cancer Center (MDACC) way of treatment of LCN-
ENs is shown in Figure 1 [24]. MDACC is currently one of the 
leading institutions in developing diagnostic and treatment 
strategy of NENs of female reproductive system. Alterna-
tive management was shown by Gadducci et al. [19]. Their 
therapeutic chart is presented on Figure 2.
OVARIAN NENS 
According to WHO 2014 classification ovarian neuro-
endocrine tumors are divided into two groups [4]. The first 
 FIGO IA1, IA2, IB1, 
IB2 and IIA 
Radical excision of 




2 cycles every 3 weeks: cisplatin 60 mg/m2 d 1 and etoposide 100 
mg/m2 d 1-3 + Teletherapy 45–50 Gy and brachytherapy 
 
Chemotherapy 2–4 cycles every 3 weeks: cisplatin 50 mg/m
2 d 1 and etoposide 100 
mg/m2 d 1–3 
 
 FIGO IB3, IIA2, IIIA, 
IIIB, IIIC1, IIIC2, IVA  Radiochemotherapy 
2 cycles every 3 weeks: cisplatin 60 mg/m2 d 1 and etoposide 100 
mg/m2 d 1–3 + Teletherapy 45–50 Gy and brachytherapy              
45–50 Gy 
 
Figo IVB Chemotherapy 
4–6 cycles every 3 weeks: cisplatin 60 mg/m2 d 1 and etoposide 120
mg/m2 d 1–3 
 
Figure 1. A therapeutic regimen in high grade cervical NETs adopted with recommendation of the MD Anderson Cancer Center
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group consists of low-grade neuroendocrine neoplasms 
resembling NEN of gastrointestinal system. They are iden-
tified as carcinoid (Carcinoid/Tumor carcinoid — TC) and 
correspond to low grade neuroendocrine tumors G1 (well 
differentiated neuroendocrine tumor/ low grade neuroen-
docrine tumor). The second category of ovarian NENs are 
poorly differentiated tumors (high grade NETs, HG NETs). 
The following types are found among HG NETs:
1. small cell carcinoma, hypercalcemic type (SCCHT),
2. small cell carcinoma, pulmonary type ( SCCPT),
3. large cell neuroendocrine carcinoma (LCNEC).
LG NENS
Carcinoids (TC) are the most common ovarian NENs. They 
account for only five percent of all carcinoids and represent 
only 0.1% of all malignant ovarian neoplasms [17]. There are 
three types of TC: 
a) a component of a mature teratoma
b) primary ovarian carcinoid 
c) metastatic carcinoid 
TC forming as a component of mature teratoma con-
stitutes about 75% cases of ovarian carcinoids. It is usually 
found as unilateral lesion, but even in 15% of cases, mature 
cystic teratoma, mucinous tumor or Brenner tumor may be 
found in opposite site. Symptoms of carcinoid syndrome 
may occur in about 1/4 to 1/3 of cases. In the WHO classifica-
tion 2014, ovarian carcinoids are included in the germinal 
ovarian tumors as teratoma with possibility of secretion 
of neuroendocrine substances that may cause carcinoid 
syndrome. Serotonin-derived molecule is secreted directly 
into the ovarian vein, bypasses the hepatic passage, and 
causes symptoms such as hot flushes, diarrheas, bronchos-
pasm or edemas. Y peptide disturbs intestinal motility and 
leads to constipations. Other substances include pancreatic 
polypeptide, gastrin or glucagon [1, 25]. The average age at 
the moment of diagnosis TC is 55 years; most patients are 
women in perimenopause or menopause.
Primary ovarian carcinoid occurs in four microscopic types: 
insular, trabecular, mucinous and stromal. The insular type re-
sembles neuroendocrine tumors of the middle segment of the 
archenteron, while the trabecular type imitates neuroendocri-
ne neoplasms from the anterior and posterior sections of the 
archenteron. The mitotic figures are rare. Microscopic structure 
of the mucinous variant is akin to an appendix carcinoid and 
three histologic subtypes are distinguished: well differentia-
ted, atypical and adenocarcinoid. Well differentiated tumors 
consist of goblet cells; however cuboidal or columnar cells 
may also occur. They infiltrate into the stroma or are located 
within the lakes of mucus. Atypical mucous carcinoid is formed 
by glandular, sieve or fine-cystic structures with moderate 
nuclear atypia. Histological structure of the adenocarcinoid 
is mixed of carcinoid and adenocarcinoma. Stromal carcinoid 
is compound of normal thyroid tissue and carcinoid, mostly 
trabecular type, rarely insular or mucinous.
Ovarian carcinoids are diagnosed in early clinical stage. 





















 FIGO IA1, IA2, IB1, 
IB2 and IIA 
Radical excision of 
the uterus with SLN 
or pelvic 
lymphadenectomy 
In case of negative LN, parametria and cut-off margin —  5–6 cycles 
of cisplatin + etoposide administered every 3 weeks 
 
In case of positive LN and /or parametria and/or cut-off margin —  3 
cycles with cisplatin + etoposide administered every 3 weeks and 
subsequent  radiochemotherapy 
 
 FIGO IB2 — IIA2 
NACT (Cisplatin + 
etoposide 3 cycles) 
In case of optimal response, radical excision of the uterus and LND 
and additional 3 cycles of cisplatin + etoposide administered every 3 
weeks. 
In  case of a suboptimal response, radiochemotherapy and  
additional 3 cycles of cisplatin/etoposide administered every              
3 weeks 
 
FIGO IIB — IVA NACT (Cisplatin + 
etoposide 3 cycles) 
radiochemotherapy and additional 3 cycles with cisplatin + 
etoposide administered every 3 weeks, and subsequent 
radiochemotherapy 
FIGO IVB  PE (Cisplatin + 
Etoposide 4–6 cycles) 
Palliative pelvic radiation therapy and of a small  single metastatic 
tumor 
Figure 2. Therapeutic procedure scheme in high grade cervical NETs developed by Gadducci
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66% of these tumors are locally advanced. Patients diag-
nosed with TC have good prognosis. Survival in stage I is 
more than 90%, but in advanced stages does not exceed 
33%. Carcinoid metastasis from gastrointestinal tract or 
lungs is mandatory. Implants outside the ovary, bilateral 
tumors, vessels infiltrations and the absence of teratoma 
elements indicate a metastatic character. Sometimes these 
tumors can be misdiagnosed as Brenner tumors, granulosa 
cell tumor or Sertoli-Leydig cells tumors. Surgery is the 
treatment of choice. Fertility sparing surgery is possible in 
patients with normal contralateral ovary and Ki-67 index 
does not exceed 5%.
HG NENS
These tumors are characterized by high mitotic activity 
and Ki-67 index usually above 30%. These features deter-
mine aggressive clinical course of HG ovarian NEN. 
Small cell carcinoma, hypercalcemic type (Fig. 3) is an ex-
ceedingly rare and lethal tumor, mostly affecting young 
women (the average age is 24 years) with aggressive clinical 
course. It develops usually unilaterally; bilateral or heredi-
tary forms are rare. The prognosis is extremely unfavorable. 
An advanced tumor with multiple metastases is found in 
about 50% of cases at the time of diagnosis. Symptoms 
of paraneoplastic hypercalcemia occur in 2/3 patients. 
This tumor can be misdiagnosed as granuloma, high grade 
ovarian cancer, dysgerminoma or other undifferentiated 
cancer. Kupryjańczyk et al. [26] described somatic and ger-
minal mutations within the SMARCA4 gene, which causes 
a lack of BRG1 protein. This may be helpful in differentiating 
from other tumors.
In small cell carcinoma, pulmonary type, metastasis from 
primary pulmonary malignancy always must be excluded. 
It is extremely rare aggressive ovarian tumor with an inci-
dence of < 1%, usually occurring in perimenopausal or post-
menopausal women (the average age is 59 years). About 
50% of cases occur bilaterally. It is diagnosed in advanced 
stages. Prognosis is poor. Patients sometimes demonstrate 
Cushing’s syndrome-like symptoms.
Ovarian large cell carcinoma usually presents as unilat-
eral lesion. An average age at the time of diagnosis is 48.5. 
It is a very rare form of cancer with an extremely aggressive 
clinical course. This neoplasm may co-exist with epithelial 
ovarian tumors such as mucinous borderline tumor, muci-
nous or serous cancers [27]. Symptoms and treatment of the 
disease are like these of ovarian cancer. The optimal surgery 
requires removal of all macroscopically lesions. An adju-
vant chemotherapy is based on the regimens with cisplatin 
Figure 3. Small cell carcinoma, hypercalcemic type  
A. Hematoxylin&eosin staning; magnification × 100. B. IHC. Positive 
synaptophysin reaction; magnification × 100. C. IHC. Positive Ki-67 
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and etoposide and minimum five cycles are recommended 
[23, 25, 27]. Treatment with somatostatin analogues can be 
considered in tumors with Ki-67 < 30% and SST receptors 
revealed in scintigraphy. In HG NETs with Ki-67 > 30% sys-
temic treatment with cytotoxic drugs is mandatory. 
SUMMARY
Neuroendocrine tumors of the cervix and ovaries are 
rare and require attentive histopathological diagnosis 
with immunohistochemical staining. The diagnosis should 
be always confirmed with chromogranin A and synapto-
physin. The Ki-67 proliferation index is not always predic-
tive or prognostic as in gastrointestinal neuroendocrine 
tumors. Ovarian carcinoids require differential diagnosis 
between primary ovarian cancers and metastases to ova-
ries, especially from the digestive system and pulmonary 
neoplasms. Treatment should be conducted by the most 
experienced oncology centers. 
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